Clinical Summary
Cerebrolysin is a porcine brain-derived neuropeptide preparation produced by Ever Neuro Pharma (Austria) since 1976. It is approximately 85% free amino acids and 15% low-molecular-weight peptides (<10 kDa), supplied as a sterile pre-mixed solution at 215.2 mg/mL of Cerebrolysin concentrate in glass ampoules (1, 2, 5, 10, 20, 30 mL sizes). Manufacturing extracts the active fractions from young-pig brain tissue via controlled enzymatic breakdown, ultrafiltration, and standardization to a defined neurotrophic-activity assay (NF-L reporter cell line, Seidl 2024 PMID 38304771). Off-brand "cerebroprotein hydrolysate" generics from Indian and Chinese manufacturers do not replicate the bioactivity (Seidl & Aigner 2024 PMID 38737662); composition equivalence is a real and active integrity issue.
Who benefits most (evidence-anchored): Adults with moderate-to-severe traumatic brain injury started within 48–72 h of injury (CAPTAIN-I + II pooled, prospective MA: medium effect size on day-90 multidimensional ensemble); patients with non-fluent post-stroke aphasia entering structured speech-language therapy (ESCAS 2025, +14.8 WAB points vs placebo); some Eastern-European pediatric neurodevelopmental contexts where it is integrated into standard rehabilitation. The benefit profile in routine acute ischemic stroke care is contested; the manufacturer-funded MA and EAN/EFNR 2021 guideline say modest benefit; the independent Cochrane review (Ziganshina 2023, PMID 37818733) says no benefit on death and a non-fatal SAE signal of harm at the 30-mL × 10-d dose.
Who likely does not benefit: Healthy biohackers seeking a "nootropic" effect; the only formal healthy-volunteer test of record is Bryan Johnson's 3-month self-trial which reported no measurable biomarker change, and the Longecity self-survey "77% response" is heavily filtered by self-selection. Patients in active malignancy (BACH1/angiogenesis pathway theoretical concern, no human data). Pregnant or lactating women (no safety data). Patients with documented porcine-protein hypersensitivity (anaphylaxis risk, Trimmel 2024 PMID 39055722).
The honest bifurcation. The Cerebrolysin evidence base does not converge. Manufacturer-funded multicenter trials (CARS, CAPTAIN, Bornstein 2018 MA, Gauthier 2015 AD MA, Strilciuc 2021 safety MA) consistently report positive effects using the Wei-Lachin / Mann-Whitney multivariate effect-size methodology applied to multidimensional ensembles of soft endpoints. Independent Cochrane reviews (Ziganshina 2023/2020, Cui 2019, Chen 2013) using GRADE on hard binary outcomes (death, SAE) find no benefit and flag a non-fatal SAE signal (RR 2.39, 95% CI 1.10–5.23) at the standard 30-mL × 10-day stroke dose. Both findings are real; they reflect different methodologies, different inclusion criteria, and different publication-bias exposures. Russian, Chinese, and Eastern-European clinical practice treats Cerebrolysin as standard-of-care across stroke, dementia, TBI, and pediatric neurology, sustained by 30+ years of usage and VED-list inclusion (1992), independently of either signal.
Research-integrity caveat. The For Better Science investigation (2024) flagged 25 of 39 Sharma cerebrolysin papers on PubPeer with multiple retractions, and 8 of 21 Masliah cerebrolysin papers under investigation; Eliezer Masliah was sacked from NIH in 2024 for research misconduct. PMID 41874695 (March 2026) is a formal retraction of a 2010 Doppler/Rockenstein Mecp2 Rett-syndrome paper. This compromises a chunk of the supportive Western preclinical literature and means each individual PMID needs to be verified against PubPeer status before citation, not just against PubMed.
Indications & Evidence
| Indication | Evidence | Type | BH | Safety | Effect Size | Population | Dose | Duration | Key PMID |
|---|---|---|---|---|---|---|---|---|---|
| Acute ischemic stroke (neuroprotection, primary endpoint) | 3/5 | UCC | 4/9 | WARN | Cochrane: RR death 0.96 (NS); non-fatal SAE RR 2.39 (1.10–5.23) | Adults, AIS within 12h | 30 mL/day IV × 10 d | 10 days | 22282884, 37818733, 32662068 |
| Stroke motor recovery (CARS protocol; adjunct to rehab) | 4/5 | PC | 6/9 | MON | MW 0.71 ARAT day-90 (CARS-1); MW 0.62 pooled (NNT 7.1 NIHSS day-14) | AIS 24-72h post-onset + standardized rehab | 30 mL/day IV × 21 d | 21 days | 26564102, 28707130 |
| Post-stroke aphasia (Broca, non-fluent) | 3/5 | UCC | 5/9 | -- | +14.8 WAB points vs placebo (p<0.001), pilot N=132 | AIS, left MCA, non-fluent aphasia | 30 mL/day IV × 10 d × 3 cycles | 90 days | 39957612 |
| Post-thrombectomy adjunct (recent, propensity-matched) | 3/5 | UCC | 4/9 | MON | mRS 0-2 OR 2.7 at 90d; aOR 6.10 at 12-mo | LVO anterior circulation post-EVT | 30 mL/day IV × 10–21 d | 10–21 days | 40325343, 41739286 |
| Moderate-severe TBI (CAPTAIN protocol) | 3/5 | UCC | 5/9 | MON | MW 0.60 day-90 multidimensional ensemble (SMD 0.34) | TBI, GCS 7–12, within 24h | 50 mL × 10 d → 10 mL × 10 d × 2 | 50 days | 31494820, 31897941, 33620612 |
| Mild-moderate Alzheimer's (cognition + global) | 3/5 | UCC | 5/9 | -- | Global change OR 4.98 at 6mo (Gauthier MA); cognition SMD -0.40 at 4 wk | AD, MMSE 14-25 | 10–30 mL/day IV × 4 wk; cycles | 4 weeks per cycle | 25832905, 20500802, 21679156 |
| Vascular dementia (cognition) | 2/5 | UCC | 3/9 | -- | Cognition SMD 0.36 (0.13-0.58), very-low-quality | Mild-mod VaD | 10–30 mL/day IV × 4 wk | 4 weeks | 31710397 |
| Pediatric; perinatal hypoxia / preterm-birth neurodevelopment | 3/5 | UCC | 4/9 | MON | Failed gross-motor 33% vs 70% (RCT, n=60, p=0.009); social/speech +46-65% (n=158) | Preterm <32wk; perinatal brain insult 6-21mo | 0.1 mL/kg weekly × 3 mo | 3 months | 26365023, 33935111 |
| Pediatric; cerebral palsy (motor) | 2/5 | AHE | 3/9 | MON | GMFCS 2.1 vs 3.16 (single RCT, n=50) | Spastic CP, 18-75 mo | 0.1-2 mL/kg weekly × 4 mo | 4 months | 28074392 |
| Pediatric, autism spectrum disorder | 2/5 | UCC | 2/9 | MON | Behavioral improvement (Russian RCT, placebo refused by parents) | ASD, 4-12 yo | 1–2 mL IM 2-3x/wk × 4 wk | 4 weeks | 29053124 |
| Post-COVID anosmia / olfactory dysfunction | 3/5 | UCC | 3/9 | -- | Olfactory threshold + identification superior to placebo | Persistent post-COVID hyposmia | 5 mL/day IV × 10 d | 10 days | 37950370 |
| Subarachnoid hemorrhage (vasospasm prevention) | 2/5 | UCC | 3/9 | MON | Trend favorable, small N | Aneurysmal SAH post-securing | 30 mL/day IV × 14 d | 14 days | 37892776 |
| CADASIL (Phase 2 ongoing) | 2/5 | AHE | 2/9 | -- | Mouse lifespan extension; human trial active not recruiting | NOTCH3 mutation carriers | TBD | TBD | 38062874 |
| Mechanism; neurotrophic factor mimicry (BDNF/NGF/GDNF) | 2/5 | ME | 4/9 | -- | NF-L bioassay confirms; not replicated by generic preparations | In vitro; reporter cell line | nM-µM | ; | 38304771, 38737662 |
| Mechanism, microglial M1→M2 polarization | 2/5 | ME | 3/9 | -- | SR of preclinical microglia studies | Mouse stroke/AD models | Variable | , | 40971139 |
| Mechanism; CREB/PGC-1α + mitochondrial | 2/5 | ME | 3/9 | -- | Restored mitochondrial function in ketamine model | Rat schizophrenia model | Variable | ; | 41204270 |
| Healthy-adult nootropic / cognitive enhancement | 1/5 | FA | 1/9 | WARN | Bryan Johnson 3-mo self-trial: NULL biomarker effect | Healthy adults | 5 mL IM daily × 20 d | 20 days | ; |
| Reverses Alzheimer's / disease modification | 1/5 | NE | 0/9 | -- | NO disease-modifying evidence; symptomatic only | , | , | , | , |
| Longevity / anti-aging | 1/5 | NE | 0/9 | -- | NO human longevity data | , | , | , | , |
Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.
Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. AHE caps at 2/5. UCC caps at 3/5. ME caps at 2/5. FA caps at 1/5. NE caps at 1/5. Note: CARS-protocol motor recovery is rated 4/5 (PC) because two independent multicenter RCTs (CARS-1 + CARS-2) plus a third independent positive RCT (ESCAS aphasia 2025) and the EAN/EFNR 2021 guideline endorsement clear the unreplicated-causal ceiling for that specific protocol. The acute-stroke primary-endpoint row stays at 3/5 because the Cochrane review found null on death; the two findings are not contradictory; they answer different questions.
Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence
BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none
Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal | AVOID Contraindicated for this indication
Star rating legend: 5/5 Multiple large RCTs + meta-analyses | 4/5 Several human RCTs | 3/5 Some human pilot data | 2/5 Animal only or very limited human | 1/5 No evidence
The CARS-Cochrane disagreement (read this if you skim nothing else)
The CARS-1 trial (Muresanu 2016 PMID 26564102, n=208) reported a Mann-Whitney effect size of 0.71 on day-90 ARAT in stroke motor recovery; extraordinarily large. The CARS-pooled MA (Guekht 2017 PMID 28707130) confirmed it across n=442. The Ziganshina 2023 Cochrane (PMID 37818733) excluded the CARS trials because their primary endpoint was the multivariate Wei-Lachin ensemble, not death. So the Cochrane "no benefit on death" finding and the CARS "huge motor-recovery effect" finding are not in conflict; they answer different questions. Read carefully: someone using Cerebrolysin in CARS-protocol post-stroke rehabilitation is using it for motor function and ADL gains. Someone using it for acute neuroprotection to reduce stroke mortality is using it for a result the Cochrane reviewers say is not there and may come with non-fatal SAE harm. These are different clinical decisions about the same drug.
Prescribing
Dosing Table
| Population | Dose | Route | Timing | Notes |
|---|---|---|---|---|
| Acute ischemic stroke (acute neuroprotection) | 30 mL/day | IV (diluted in 100-250 mL saline, infused 15-60 min) | Daily × 10 days | Within 12 h of stroke onset; Cochrane null on death + SAE harm signal; informed-consent decision |
| Stroke motor recovery (CARS protocol) | 30 mL/day | IV | Daily × 21 days | Started 24-72 h post-stroke; paired with structured PT/OT; the rehab is the active comparator base |
| Post-stroke aphasia (ESCAS protocol) | 30 mL/day | IV | Daily × 10 d × 3 cycles (10-day washouts) | Paired with daily speech-language therapy |
| TBI (CAPTAIN protocol) | 50 mL × 10 d → 10 mL × 10 d × 2 cycles | IV | First-cycle high-dose loading | Started within 24 h of injury; total 50-day program |
| Mild-mod Alzheimer's | 10–30 mL/day | IV | 5 days/week × 4 weeks; cycles 2-4×/year | Higher dose (30 mL) showed best global response |
| Vascular dementia | 10–30 mL/day | IV | 5 days/week × 4 weeks | Modest benefit; weak evidence |
| Pediatric perinatal/preterm (Russian/Iranian protocol) | 0.1 mL/kg | IM | Weekly × 12 weeks | Must be specialist-supervised; no FDA pediatric data |
| Pediatric cerebral palsy | 0.1-2 mL/kg | IM | Weekly × 16 weeks | ; |
| Community nootropic (Russian/Eastern-European custom) | 5 mL/day | IM | Daily × 10-20 days, 1-4 cycles/year | Not evidence-based for healthy adults; Bryan Johnson null trial |
| Bryan Johnson healthy-adult self-trial | 5 mL/day | IM | Daily × ~3 months | NULL biomarker effect reported |
IM injection note: IM Cerebrolysin is famously painful; community reports describe "burning" lasting several minutes. Pain is the top complaint in self-administered courses and frequently dose-limiting. Slow injection rate (>30 sec) and warming the ampoule to body temperature partially mitigate.
Formulation Table
| Form | Bioavailability | When to Use | Cost (retail import) |
|---|---|---|---|
| 1 mL ampoule (215 mg) | IM 100% (allowing for first-pass clearance of free amino acids) | Pediatric, low-dose ambulatory | $4-8/ampoule |
| 5 mL ampoule (1076 mg) | IM/IV 100% | Standard ambulatory dose; community nootropic course | $8-15/ampoule |
| 10 mL ampoule (2152 mg) | IV 100% | Inpatient course; mid-dose AD/dementia | $15-25/ampoule |
| 20 mL ampoule (4304 mg) | IV 100% | Inpatient stroke/TBI dose component | $25-40/ampoule |
| 30 mL infusion vial (6456 mg) | IV 100% | Stroke standard-of-care daily IV course | $40-60/vial |
| Counterfeit "cerebroprotein hydrolysate" (Indian/Chinese generic) | Unknown; bioactivity NOT replicated per Seidl & Aigner 2024 | Should not be used as Cerebrolysin equivalent | Variable |
Route ranking: IV 4/5 (clinical standard, full bioavailability, most evidence) > IM 3/5 (ambulatory, painful, all approved indications also have IM dosing) > Oral "Memoprove" (CosmicNootropic) 1/5 (bioavailability unknown, no clinical data, not recommended)
Condition-Specific Protocols
Acute Ischemic Stroke; Two Decisions, Two Protocols
Evidence: Mortality endpoint 3/5 Cochrane null; CARS motor-recovery endpoint 4/5 | Key PMIDs: 22282884 (CASTA), 26564102 (CARS-1), 28707130 (CARS pooled), 37818733 (Cochrane 2023)
Decision 1: Acute neuroprotection (within 12h, primary endpoint death/severe disability). The Cochrane 2023 review is the cleanest read: 7 RCTs, n=1773, RR death 0.96 (NS), non-fatal SAE RR 2.39 (1.10-5.23) at the 30-mL × 10-d dose. The Cochrane reviewers conclude probable harm outweighs probable benefit in this specific use. AHA/ASA 2019 does not recommend Cerebrolysin (Class III LOE A neuroprotective category). Conservative read: not recommended for acute neuroprotection in patients otherwise receiving standard-of-care thrombolysis or thrombectomy. Russian, Chinese, and Eastern-European practice continues to use it routinely; this reflects 30 years of clinical inertia rather than fresh trial data.
Decision 2: Motor recovery in subacute rehabilitation (24-72h post-stroke + structured PT). The CARS-1 (PMID 26564102) and CARS-pooled (PMID 28707130) trials report large effect sizes (MW 0.71/0.62 on ARAT day-90). The 2025 ESCAS aphasia trial (PMID 39957612) is an independent positive replication on a related rehabilitation indication. The EAN/EFNR 2021 guideline (PMID 34152062) recommends Cerebrolysin 30 mL/day IV ≥10 days for early motor neurorehabilitation as an evidence-based add-on (Class; manufacturer-affiliated panel COI flagged). More defensible use case than acute neuroprotection.
Phase 1 (Acute, 0-72h): decision-point. If acute neuroprotection is the goal, the evidence does not support routine use; Cochrane signals net harm. Consider only in centers where Cerebrolysin is the local standard and informed consent has acknowledged the SAE signal.
Phase 2 (Rehabilitation, 24h-21d): if motor or speech recovery is the goal and structured rehabilitation is in place, the CARS protocol (30 mL/day IV × 21 days, paired with daily PT/OT) is the evidence-based regimen.
Phase 3 (Maintenance, 1mo+): repeat 10-21 day cycles every 3-6 months if continued recovery progress, per Russian/Eastern-European practice. No high-quality evidence for maintenance.
Drug Interaction Timing: do not co-infuse with amino-acid IV solutions (pH/buffer incompatibility documented in product label). Avoid concurrent MAO inhibitors. Statins, antihypertensives, anticoagulants; no documented interaction. Concurrent thrombolysis (tPA): no formal contraindication, but the Cochrane non-fatal SAE signal warrants caution.
Expected Outcomes: ARAT day-90 effect size MW 0.62 (CARS pooled); NIHSS improvement +1.39 points (Patel 2025 MA); modified Rankin Scale 0-2 OR 2.7 at 90d in propensity-matched post-thrombectomy cohort (Staszewski 2025).
Stop/Reassess Criteria: anaphylaxis (rare but documented; Trimmel 2024 PMID 39055722 in 85-year-old subacute stroke patient); persistent agitation/insomnia; non-fatal SAE per Cochrane signal (review chart at day 7).
Moderate-Severe TBI; CAPTAIN Protocol
Evidence: 3/5 | Key PMIDs: 31494820 (CAPTAIN-I), 31897941 (CAPTAIN-II), 33620612 (CAPTAIN pooled MA)
Phase 1 (Loading, days 1-10): 50 mL/day IV diluted in 250 mL saline, infused over 60-90 min, started within 24 h of injury, daily × 10 days. Started after hemodynamic stability and ICP control are established.
Phase 2 (Consolidation cycles, days 21-50): 10 mL/day IV × 10 days × 2 cycles (separated by 10-day washouts). Total program ~50 days.
Phase 3 (Maintenance): repeat 10 mL × 10 d cycles every 3 months × 12 months per Eastern-European post-acute neurorehab protocols.
Expected Outcomes: day-90 multidimensional 13-scale ensemble Mann-Whitney 0.59 (CAPTAIN-II); pooled SMD 0.34 (CAPTAIN MA). Translates to "small-to-medium meaningful clinical benefit" on cognition + ADL + neuropsych battery.
Stop/Reassess Criteria: rising ICP; status epilepticus (pro-convulsant theoretical risk in seizure-prone TBI; manufacturer warning); allergic reaction.
Mild-Moderate Alzheimer's
Evidence: 3/5 | Key PMIDs: 25832905 (Gauthier MA), 20500802 (dose-finding), 21679156 (combo with donepezil)
Phase 1 (Initiation): 30 mL/day IV (the higher dose performed best in Alvarez 2011 dose-finding) × 5 days/week × 4 weeks.
Phase 2 (Cycle repetition): 10-30 mL × 4-week cycles, 2-4 cycles per year. The Alvarez 2011 combo trial (PMID 21679156) showed 10 mL Cerebrolysin ≈ donepezil 10 mg on cognitive endpoints; combination trended best on global outcome.
Reassessment criteria: MMSE/ADAS-cog at baseline, end of cycle, and 3 months post-cycle. The Gauthier 2015 MA effect persists 6 months post-treatment for global change (OR 4.98) but cognition effect attenuates earlier (4-week peak SMD -0.40, fades by 6 months).
Important framing: modest symptomatic benefit. Not disease-modifying. The community claim "Cerebrolysin reverses Alzheimer's" has no evidentiary basis.
Safety
Interactions
| Interactant | Effect | Management | Evidence |
|---|---|---|---|
| MAO inhibitors (phenelzine, selegiline, etc.) | Theoretical hypertensive crisis | Avoid; manufacturer label contraindication | Manufacturer label; mechanism (free amino acids include tyrosine precursors) |
| Amino acid IV solutions (TPN) | Buffer/pH incompatibility | Do NOT co-infuse; separate IV lines or sequential infusion with saline flush between | Manufacturer label |
| Antidepressants (SSRI, SNRI, TCA) | Theoretical synergistic CNS activation, agitation | Monitor; consider morning-only Cerebrolysin dosing | Manufacturer label; community reports |
| Sympathomimetics (decongestants, stimulants) | Theoretical hypertensive synergy | Avoid combination during course | Manufacturer label |
| Sedatives, alcohol | Antagonism of cognitive activation | No safety risk; expect reduced subjective effect | Mechanism |
| Concurrent thrombolysis (tPA) | Non-fatal SAE signal in Cochrane stroke review | Risk-benefit decision; informed consent | PMID 37818733 |
| Levodopa | Theoretical synergy on dopaminergic function | No clinical data; Russian practice combines them | Russian practice |
| Anticoagulants (warfarin, DOACs) | No documented interaction | Standard monitoring | None reported |
Contraindications
- Known hypersensitivity to porcine proteins (anaphylaxis risk; Trimmel 2024 PMID 39055722)
- Status epilepticus or active uncontrolled seizure disorder (pro-convulsant theoretical risk; manufacturer warning)
- Severe renal impairment (free amino acid load; manufacturer caution)
- Pregnancy and lactation (no safety data; default avoidance)
- Active malignancy or history of cancer within 5 years (BACH1/angiogenesis/BDNF pathway theoretical concern, no human data)
- Concurrent MAO-inhibitor therapy
- Religious-dietary restriction (porcine origin) where this is operationally meaningful
Adverse Effects (ranked by frequency)
| Effect | Frequency (clinical) | Community frequency | Severity |
|---|---|---|---|
| Injection-site pain (IM) | Common | Top complaint; "burning" | Mild-moderate, dose-limiting in some |
| Headache | Common (~5-10%) | High; sometimes dose-limiting | Mild-moderate |
| Increased sweating, body-odor change | Reported | Moderate; distinctive cluster | Mild |
| Dizziness, vertigo | Common | Moderate | Mild |
| Agitation, jitteriness, insomnia (evening dosing) | Reported | Moderate; drives "morning-only" community rule | Mild-moderate |
| Nausea, GI upset | Reported | Moderate | Mild |
| Confusion, tremor | Reported | Rare in community | Mild-moderate |
| Hypertension (transient, infusion-related) | Uncommon | Rarely reported | Mild |
| Anaphylaxis | Rare (Trimmel 2024 case report) | Rarely reported | Life-threatening |
| Sinus node dysfunction | Single FAERS report (#13251227) | Not in community reports | Serious |
| Non-fatal SAE (Cochrane signal at 30 mL × 10 d) | RR 2.39 (1.10-5.23) | ; | Variable |
FAERS Signal Table (BioMCP; 78 total reports)
| Reaction | FAERS Reports (suspect-only) | Suspect Drug? | Seriousness | Linked Indication | Notes |
|---|---|---|---|---|---|
| Drug ineffective | 11 | Yes | Variable | Multiple | Non-medical signal; reflects expectations |
| Tremor | 8 | Yes | Variable | Stroke, AD | Dose-related, recoverable |
| Cognitive disorder | 7 | Yes | Serious | AD, dementia | Confounded by indication |
| Depression | 7 | Yes | Variable | Multiple | Confounded; depression common in stroke/AD/TBI populations |
| Pyrexia | 7 | Yes | Mild | Multiple | Possibly infusion-related |
| Diarrhoea | 6 | Yes | Mild | Multiple | ; |
| Dyspnoea | 6 | Yes | Variable | Multiple | Watch in cardiac/respiratory comorbidity |
| Multiple sclerosis relapse | 6 | Yes | Serious | MS (off-label use) | Off-label MS use confound; not on-label indication |
| Pain in extremity | 6 | Yes | Mild | Multiple | Possibly injection-site related |
| Urinary incontinence | 6 | Yes | Variable | Stroke, AD | Indication-confounded |
| Cerebral haemorrhage | 2 | Concomitant only | Serious | Stroke | Co-administered with anticoagulants |
| Sinus node dysfunction | 1 (report #13251227) | Yes | Serious | Stroke | Single suspect cardiac signal |
| Anaphylaxis | (Literature, not FAERS) | Yes | Life-threatening | TBI | Trimmel 2024 PMID 39055722; well-documented case |
Reading FAERS data: The 78 total reports reflect Cerebrolysin's non-FDA-approved status in the US. Reports are dominated by EU-cross-reported events filtering through OpenFDA. The dataset is too small to be evidentiary on its own; the Cochrane non-fatal SAE signal (RR 2.39) at the 30-mL × 10-d dose is the higher-quality safety datum.
Monitoring Table
| Test | When | Target |
|---|---|---|
| Vital signs (BP, HR) | First IV infusion, then daily | Stable; hypertension >160/100 → slow rate |
| CBC, CMP | Baseline, end of course | Stable; no leukopenia/eosinophilia signal historically |
| Allergic-reaction history | Baseline | No prior reaction to porcine proteins |
| ICH-risk markers (concurrent anticoagulant) | Baseline + day 7 | Coag panel if applicable |
| Cognitive battery (AD/dementia indication) | Baseline + end of cycle + 3 mo | MMSE / ADAS-cog / global assessment |
| ARAT or motor-function score (stroke) | Baseline + day 90 | Per CARS protocol |
Special Populations
Renal Impairment
| GFR Range | Dose Adjustment | Rationale | Evidence |
|---|---|---|---|
| 60-89 (mild) | Standard | Free amino-acid load is small relative to dietary protein | Manufacturer label |
| 30-59 (moderate) | Reduce dose 25-50% or extend cycle | Free amino-acid clearance reduced | Manufacturer label |
| <30 (severe) | Avoid or specialist consult | Risk of azotemia exacerbation | Manufacturer label |
Hepatic Impairment
| Severity | Dose Adjustment | Rationale | Evidence |
|---|---|---|---|
| Child-Pugh A (mild) | Standard | No major hepatic metabolism | Manufacturer label |
| Child-Pugh B (moderate) | Standard with monitoring | Limited data | Manufacturer label |
| Child-Pugh C (severe) | Specialist consult | No safety data | Manufacturer label |
Pregnancy and Lactation
No safety data. Default to avoidance. No human pregnancy outcome data; no animal teratogenicity data published in indexed sources.
Pediatrics
Off-label in Western neurology; integrated into Russian/EE practice. Pediatric evidence base is small Iranian/Russian/Egyptian RCTs. No multi-center Western pediatric RCT has been completed. Specialist-supervised use only; the autism-spectrum data (Chutko 2017 PMID 29053124) comes from a region with documented research-integrity concerns and no placebo arm (parents refused).
Synergies & Stacking
| Co-nutrient/Drug | Why | Evidence |
|---|---|---|
| Donepezil (in AD) | Combo trended best on global outcome vs monotherapy | Alvarez 2011 PMID 21679156 |
| Citicoline | Concurrent neurotrophic + cholinergic precursor; combined TBI study favorable trend | NCT06052787 + retrospective Schlager 2025 (PMID 41409218) |
| Standardized PT/OT (in stroke recovery) | The CARS effect requires structured rehabilitation as the active comparator base | PMID 26564102, 28707130 |
| Standardized speech-language therapy (in aphasia) | The ESCAS effect requires SLT as base | PMID 39957612 |
| Lithium (preclinical depression model) | Synergistic on CREB/PGC-1α | PMID 38394763 (preclinical) |
| Nicotinamide (preclinical post-MCAO) | Combined improved cognitive recovery | PMID 38734304 (preclinical) |
| Semax (Russian peptide stack) | Community "Russian stack"; no human RCT | Anecdotal |
| Selank (Russian peptide stack) | Community anxiolytic + cognitive layering; no human RCT | Anecdotal |
| Modafinil | Wakefulness layering; no RCT data | Anecdotal |
| Lion's Mane / Citicoline (community natural stack) | Theoretical neurotrophic stacking; no RCT | Anecdotal |
| Amino-acid IV solutions (TPN) | DO NOT co-infuse; pH/buffer incompatibility | Manufacturer label |
| MAO inhibitors | Contraindicated | Manufacturer label |
Individual Response Modifiers
Sex-Specific Considerations
| Factor | Male | Female | Clinical Implication |
|---|---|---|---|
| Stroke outcomes baseline | Better baseline | Worse baseline globally | Whether Cerebrolysin closes the gap is unstudied; no trial has reported a primary sex-stratified outcome to date. Genuine evidence gap. |
| Body composition (mg/kg dosing) | Higher lean mass | Lower lean mass | The IV doses in adult trials are not weight-based, so this matters less than for weight-based agents. Pediatric dosing IS weight-based (0.1 mL/kg). |
| Pregnancy / lactation | N/A | No safety data; default avoidance | Hard rule for women of childbearing age |
| Autoimmune prevalence (MS, lupus) | Lower rates | 2-10× higher rates | The FAERS MS-relapse cluster (n=6) is concerning given off-label MS use predominates in women. Avoid Cerebrolysin in active autoimmune disease until autoimmune-specific evidence emerges. |
Genetic Modifiers
| Gene (SNP) | Variant | Effect on This Compound | Evidence | Action |
|---|---|---|---|---|
| APOE | e4/e4 | Altered AD trajectory and Aβ clearance; theoretical lower Cerebrolysin response in advanced AD | Inferential from AD trial subgroup post-hocs; not formally tested | Consider when interpreting AD-cycle response; e4/e4 may show smaller cognitive effect |
| NOTCH3 | CADASIL mutation | Cerebrolysin currently in Phase 2 for CADASIL (NCT05755997) | Mouse lifespan extension PMID 38062874; human data pending | If CADASIL diagnosis confirmed, the Phase 2 trial result will determine; until then, off-label compassionate use only |
| HLA class II porcine-protein hypersensitivity | Unspecified | Theoretical anaphylaxis predisposition | Inferential from Trimmel 2024 case report | History of red-meat / pork allergy → avoid |
| CYP-mediated metabolism | Various | Cerebrolysin is not significantly CYP-metabolized | No interaction reported | Standard interactions do not apply |
| MTHFR / MAO polymorphisms | Various | Theoretical interaction with amino-acid load | No human data | Speculative; no action |
No formal pharmacogenomic dosing recommendations exist. The compound's neurotrophic-mimicry activity is dose-relevant in ways not captured by standard CYP-based PGx tools.
Community & Anecdotal Evidence
Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, recall bias, and vendor-funded astroturfing are inherent. Presented for completeness, not as medical guidance.
Dominant Sentiment
Mixed-to-positive with heavy self-selection bias. Across r/Nootropics, r/Biohackers, r/Peptides, Longecity, Looksmax, biohacker YouTube, and US IV-clinic patient testimonials (~150-200 identifiable reports), approximately 70-77% of self-reporters claim noticeable cognitive lift; 20-30% non-responders. Bryan Johnson's documented null biomarker result after a 3-month self-trial is the single most prominent contrarian datapoint and deserves equal weight to the self-reported "responder" testimonials.
What Users Report
| Reported Effect | Frequency | Typical Onset | Source Communities |
|---|---|---|---|
| Clearer thinking, working memory | Common | Days 5-7 of course | r/Nootropics, Longecity, biohacker YouTube |
| "Calm focus," anxiolysis | Common | Days 3-5 | Longecity, r/Nootropics |
| Verbal fluency improvement | Moderate | Days 5-10 | Longecity logs, ADHD-cycle reports |
| Reduced anhedonia, improved motivation | Moderate | Days 5-14 | Longecity, depression-stack reports |
| Better sleep architecture (some); insomnia (others) | Bimodal | Variable | Both signals present in community |
| TBI / concussion subjective recovery | Strong (smaller N) | Days 3-10 | r/TBI, athlete forums |
| Long-COVID brain fog improvement | Emerging (small N) | Days 7-14 | r/LongCovid, post-COVID Discord |
| Pediatric off-label "speech progress" | Reported (ethically fraught) | Weeks 2-4 | Russian/EE parent forums; small DAN/MAPS-adjacent US communities |
| No subjective effect | ~20-30% non-responders + Bryan Johnson | ; | All communities |
Community Dosing vs Clinical
| Source | Dose | Route | Notes |
|---|---|---|---|
| Animal stroke models | Variable | IV | Preclinical |
| CARS/CAPTAIN clinical | 30-50 mL/day IV | IV | Inpatient supervised |
| Community nootropic course (Russian/EE custom) | 5 mL/day | IM | 10-20 days, 1-4 cycles/year |
| US biohacker IV-clinic | 5-30 mL IV per session | IV | 10-treatment package, then maintenance |
| Bryan Johnson | 5 mL/day IM | IM | ~3 months continuous |
| Aggressive cognitive enhancement (Longecity) | 5-10 mL IM 5d/wk × 4 wk | IM | ; |
| Pediatric off-label community (Eastern European parent forums) | 1-2 mL IM 2-3×/wk × 4 wk | IM | No FDA/Western pediatric safety data at home-administered scale |
Note that community dosing largely mirrors clinical dosing; there is no dramatic folk-protocol divergence the way there is with BPC-157 (where biohackers wildly outpace clinical evidence).
Popular Stacks (Community)
| Stack | Reported Purpose | Evidence Level |
|---|---|---|
| Cerebrolysin + Semax | "Russian stack"; anxiolysis + cognition | Anecdotal only |
| Cerebrolysin + Selank | Anxiolytic + cognitive layering | Anecdotal only |
| Cerebrolysin + Noopept / Phenylpiracetam | Russian racetam stack | Anecdotal only |
| Cerebrolysin + Modafinil | Wakefulness layering | Anecdotal only |
| Cerebrolysin + Lion's Mane / Citicoline | "Natural" companion stack | Anecdotal only |
| Cerebrolysin + Donepezil | Clinical AD combo (real evidence) | PMID 21679156 |
| Cerebrolysin + LDN + GLP-1 + methylene blue | Emerging long-COVID stack | Anecdotal, growing |
| Cerebrolysin + thrombolysis (clinical) | Acute stroke neuroprotection | Cochrane null + SAE signal |
Red Flags & Skepticism Notes
- Sharma/Masliah/EVER Pharma research-integrity scandal (For Better Science 2024); 25/39 Sharma cerebrolysin papers under PubPeer scrutiny; 8/21 Masliah cerebrolysin papers under investigation; multiple retractions. Eliezer Masliah was sacked from NIH in 2024 for research misconduct. PMID 41874695 (March 2026) is a formal retraction notice (Doppler/Rockenstein Mecp2 Rett 2010 paper). Individual PMID checks against PubPeer are now mandatory before citation.
- Bryan Johnson halo effect. His 3-month self-trial reported NO measurable biomarker effect, yet US IV clinics frequently leverage his name in marketing without disclosing the null result.
- Vendor-funded "editorial" content. Limitless Mindset (Jonathan Roseland), CosmicNootropic blog, peptide-blog sites (realpeptides.co, peptidesinstitute.org, peptideprotocolwiki.com) repurpose vendor copy as community content. The "BDNF +600%" stat traces to a single Cerebrolysin + Donepezil Alzheimer's trial; being repurposed for healthy biohackers without that context.
- US IV-clinic marketing. NexGen Health (San Jose), Unchained Wellness (AZ), Wellness at Century City (LA), Axon Integrative Health (Denver), InfuzeMD, RWA Center (Beverly Hills) use near-identical "brain regeneration / neuroregeneration / CNS regeneration / self-repair" copy traceable directly to manufacturer EVER Pharma marketing. Pricing ($200-500 per IV session, $2,000-5,000 per 10-day course) is poorly disclosed.
- Russian/EU appeal-to-tradition narrative. "Used safely for 50+ years in Europe"; true on the timeline, misleading on what "safe" was tested for and how rigorously. Pre-2000 European pharmacovigilance for this category is sparse.
- Counterfeit substitution risk. Indian and grey-market "cerebroprotein hydrolysate" products sold as Cerebrolysin equivalents. Seidl & Aigner 2024 (PMID 38737662) documents that several "Cerebrolysin-like" generic preparations lack neurotrophic bioactivity. Pure Lab Peptides, Nu Science Peptides, Peptide.shop, Nationwide Peptides, and similar US-facing research-chemical vendors sell powders or solutions of unverifiable composition.
- Pediatric autism RCTs without placebo arms. Multiple cited RCTs explicitly state parents refused enrollment in placebo arms; a citation flag. Cannot be treated as efficacy evidence.
- Russian/Chinese practice as evidence. Cerebrolysin's VED-list inclusion (1992) and CSA off-guideline ubiquitous use are facts about clinical inertia, not facts about efficacy. Treat them as context, not endorsement.
Folk vs Clinical Reality Check
Where community experience aligns with clinical data: Side-effect catalog (sweating, headache, IM pain, agitation/insomnia on evening dosing) matches the SmPC. TBI subjective recovery aligns with the CAPTAIN-pooled positive signal. Aphasia subjective recovery aligns with the ESCAS pilot. Modest cognitive benefit in vascular dementia aligns with the Cochrane very-low-quality positive SMD.
Where community experience diverges from clinical data: The "reverses Alzheimer's" claim, there is no disease-modifying evidence; only symptomatic and modest. The "BDNF +600%" claim, real number, but only in donepezil-cotreatment context, not in healthy biohackers. The "dramatically better than other nootropics" magnitude, no head-to-head supports it. The "safe because used 50 years in Europe" framing, appeals to tradition; long-term healthy-user safety is genuinely under-studied. The "reliable nootropic for healthy people"; Longecity self-survey is biased (~77% response self-selected); Bryan Johnson's null deserves equal weight; the only formal healthy-volunteer EEG study is small and methodologically weak. The "pediatric autism efficacy" claim; supporting trials are small, mostly placebo-uncontrolled (parents refused), from regions with research-integrity concerns; cannot be cited as efficacy evidence.
Deep Dive: Mechanisms & Research
Neurotrophic-factor mimicry
Cerebrolysin's pharmacodynamic effect is most plausibly explained by mimicry of endogenous neurotrophic factors, BDNF, NGF, GDNF, CNTF, through the <10 kDa peptide fraction. The bioactivity is preserved by the manufacturer's standardized neurofilament-light-chain (NF-L) reporter cell-line bioassay (Seidl 2024 PMID 38304771), which is the differentiator between authentic Cerebrolysin and the generic "cerebroprotein hydrolysate" preparations that lack equivalent activity (Seidl & Aigner 2024 PMID 38737662).
The mechanism is supported by:
- BDNF / dendritic plasticity restoration in rat amygdala (maternal-deprivation model, Cárdenas-Bedoya 2025 PMID 40123021)
- GAP-43 (axonal growth marker) increase post-kainic-acid lesion (Martínez-Torres 2024 PMID 39580783)
- CREB/PGC-1α pathway activation in ketamine schizophrenia model (Hosseini 2025 PMID 41204270)
Anti-amyloid / extracellular-vesicle modulation
Alvarez 2022 (PMID 36155516) reported that Cerebrolysin treatment modulates plasma-derived extracellular vesicle Aβ and tau profiles in mild-moderate AD patients. This is mechanistically plausible and consistent with the modest cognitive benefit observed in AD trials, but does NOT translate to disease-modification claims.
Microglial M1→M2 polarization
Chan 2025 (PMID 40971139) systematic review of preclinical microglia studies found a consistent M1 (pro-inflammatory) → M2 (anti-inflammatory / repair) polarization signal across stroke and AD models. This mechanism fits the broad indication portfolio (stroke, TBI, AD, VaD) but is preclinical only.
Anti-apoptotic and BBB protection
Akbari-Gharalari 2026 (PMID 40470992) reported Cerebrolysin-loaded PRP exosomes modulating TNF-α/IL-10 in spinal cord injury; preclinical only.
Clinical Trials (from BioMCP / ClinicalTrials.gov)
| NCT ID | Title (abbreviated) | Phase | Status | Conditions | N | Key Dates |
|---|---|---|---|---|---|---|
| NCT00868283 | CASTA; Asian acute stroke | IV | Completed | AIS | 1070 | 2009 |
| NCT06897176 | Cerebrolysin in stroke (latest) | IV | Recruiting | AIS | TBD | 2025+ |
| NCT04904341 | Cerebrolysin + thrombectomy (Staszewski) | III | Unknown | AIS post-EVT | 100 | 2021+ |
| NCT07043686 | Early stroke rehab | NA | Recruiting | Stroke | TBD | 2024+ |
| NCT00911807 | Cerebrolysin in AD | II | Completed | Alzheimer's | TBD | 2009-2014 |
| NCT01822951 | Cerebrolysin vs memantine in AD | IV | Withdrawn | Alzheimer's | 0 | 2013 |
| NCT00947531 | Vascular dementia | IV | Completed | VaD | 242 | ; |
| NCT01606111 | CAPTAIN-I | IV | Terminated | TBI | 46 | (slow enrollment) |
| NCT06052787 | Cerebrolysin + citicoline TBI | III | Completed | TBI | TBD | 2023 |
| NCT01787123 | Cerebrolysin in SAH | II/III | Completed | SAH | TBD | ; |
| NCT06899464 | CLINCH ICH | IV | Not yet recruiting | Lobar ICH | 88 planned | 2025+ |
| NCT01059461 | HIE infants | II | Completed | Perinatal HIE | TBD | ; |
| NCT03506841 | Preterm CP | I | Completed | Preterm/CP | TBD | ; |
| NCT04751136 | Down syndrome | II | Completed | DS | TBD | ; |
| NCT05755997 | CADASIL Phase 2 | II | Active, not recruiting | CADASIL | TBD | 2023+ |
| NCT04830943 | Post-COVID anosmia | III | Completed | Persistent anosmia | TBD | 2021-2023 |
| NCT05821075 | Bell palsy | I/II | Recruiting | Bell palsy | TBD | 2023+ |
| NCT06677502 | Cognitive impairment in critically ill | NA | Enrolling by invitation | ICU cognitive | TBD | 2024+ |
Total registered: 40 trials. Manufacturer (EVER Neuro Pharma GmbH) sponsors most industry trials.
Regulatory Status (from BioMCP)
- FDA: Not approved. No NDA on file. Not on the FDA bulk drug substances list approved for compounding. Orphan-drug designation entry exists (FDA accessdata cfgridkey 513315), designation only, not approval. No specific FDA import alert located in the database via this session's tools, personal-import enforcement is at FDA officer discretion under the Personal Importation Policy (CPG 9-71); 90-day-supply allowance commonly invoked. No FDA warning letter to a US compounding pharmacy or importer specifically for Cerebrolysin found.
- EMA: Not centrally authorized. National authorizations only. Marketing authorization holder: EVER Neuro Pharma GmbH (Unterach am Attersee, Austria). EMA assigned Cerebrolysin to the 13-year PSUR cycle reserved for very-well-established-safety drugs. Approved nationally in Austria (origin), Germany, Romania, Czech Republic, Slovakia, Poland, Hungary, Bulgaria, Switzerland.
- Russia: On the List of Vital and Essential Medicines since 1992. RU MoH guideline: AIS, vascular dementia, AD, TBI, pediatric neurodevelopmental.
- China: Approved; CSA 2023 guideline gives weak/Class III recommendation for stroke (PMID 38158224). Massive off-guideline real-world inpatient use.
- Mexico: COFEPRIS-approved; routine hospital use.
- United Kingdom, Canada, France, most of Western Europe ex-Austria/Germany: Not approved.
- WADA: Not on 2026 Prohibited List as a named substance. Peptide-mimetic categorization under S2; UNVERIFIED for current monograph; athletes should treat as caution regardless of absence from explicit named-substance lists.
Ataraxia Verdict (as of 2026-04-29)
Evidence Classification (Mode 5: Evidence Classifier)
| Claim | Relationship | Bradford Hill | Safety Flag | Key Weakness |
|---|---|---|---|---|
| Stroke motor recovery (CARS protocol) | PC | 6/9 | MON | Manufacturer-funded; multivariate Wei-Lachin endpoint not standard; CARS-2 standalone PMID unverified |
| Acute-stroke neuroprotection (mortality endpoint) | UCC | 4/9 | WARN | Cochrane null on death + non-fatal SAE signal RR 2.39; AHA/ASA does not recommend |
| Post-stroke aphasia (ESCAS 2025) | UCC | 5/9 | -- | Single pilot RCT (n=132); needs replication |
| TBI recovery (CAPTAIN protocol) | UCC | 5/9 | MON | CAPTAIN-I terminated underpowered; CAPTAIN-II single-center Romania; pooled positive but small N |
| Mild-mod Alzheimer's (cognition + global) | UCC | 5/9 | -- | Modest symptomatic benefit; not disease-modifying; effect attenuates by 6mo |
| Vascular dementia (cognition) | UCC | 3/9 | -- | Cochrane very-low-quality; "may be too small to be clinically meaningful" |
| Pediatric perinatal/preterm | UCC | 4/9 | MON | Single Iranian/Egyptian RCTs; no Western multicenter replication |
| Pediatric autism | UCC | 2/9 | MON | Russian RCT, parents refused placebo arm; integrity-flagged region |
| Healthy-adult nootropic | FA | 1/9 | WARN | Bryan Johnson null; only formal HV EEG study small/weak |
| BDNF +600% in healthy adults | NE | 0/9 | -- | Stat from Cerebrolysin + donepezil AD trial; not generalizable |
| Disease modification in AD | NE | 0/9 | -- | Symptomatic only; no disease-modifying evidence |
| Longevity / anti-aging | NE | 0/9 | -- | NO human data |
Hype Check (Mode 1: Fallacy Radar)
- Appeal to tradition: "Used safely for 50+ years in Europe"; argument from age, not evidence. Pre-2000 pharmacovigilance was sparse. ✓ Detected.
- Appeal to authority: "Approved in 50+ countries" used as efficacy claim. Approval is a regulatory fact, not an efficacy signal; Russia's VED-list inclusion since 1992 reflects state pharmaceutical-purchasing policy, not RCT-based efficacy. ✓ Detected.
- Hasty generalization: Animal/mechanistic neurotrophic-mimicry data extrapolated to "neuroregeneration in healthy adults." ✓ Detected.
- Cherry-picking: Manufacturer-funded MAs cited without the Cochrane null. ✓ Detected widely.
- Unit-stripped statistics: "BDNF +600%" decontextualized from donepezil-cotreatment AD population. ✓ Detected.
- Argument from popularity: "Russian doctors prescribe it, Bryan Johnson tried it"; neither establishes efficacy in any specific use. ✓ Detected.
- False equivalence: "Cerebrolysin is the original; cerebroprotein hydrolysate is the same"; Seidl & Aigner 2024 directly refuted. ✓ Detected.
Evidence Gaps
- No primary sex-stratified outcome in any major Cerebrolysin RCT (women have worse stroke outcomes; does Cerebrolysin help close that gap? Unknown.)
- No multi-center Western pediatric RCT. Pediatric evidence is regional (Iranian/Egyptian/Russian) and small.
- No formal head-to-head vs citicoline, piracetam, or memantine (NCT01822951 vs memantine was withdrawn).
- No long-term safety beyond 5-year follow-up in any indication.
- No formal healthy-adult biomarker study beyond Bryan Johnson's self-trial. The HV EEG study cited in some reviews is small and methodologically weak.
- Sharma/Masliah literature; until each PMID is independently re-verified against PubPeer, the supportive Western preclinical base is partially compromised.
- CARS-2 standalone publication; only the pooled MA (PMID 28707130) is indexed; individual CARS-2 trial PMID is UNVERIFIED.
- Composition equivalence; generic "cerebroprotein hydrolysate" preparations are sold as substitutes but documented to lack bioactivity. The downstream consumer cannot reliably distinguish authentic EVER-Pharma Cerebrolysin from generic substitutions.
Bias Flags (Mode 4: First Principles)
- Manufacturer dependence. EVER Neuro Pharma GmbH funds the multicenter trials, employs the statisticians (Wei-Lachin / Mann-Whitney methodology preferred), and has authors on the EAN/EFNR 2021 guideline panel. This is structural, not malicious; but it means the manufacturer-funded literature should be weighted independently from the Cochrane independent-reviewer assessments.
- Methodology choice as advocacy. The Wei-Lachin multivariate ensemble + Mann-Whitney effect-size on 13-scale soft outcomes is a defensible statistical choice that consistently produces positive results. The Cochrane GRADE on hard binary outcomes (death, SAE) is a defensible choice that consistently produces null/harm signals. Both are valid; the choice shapes the answer.
- Geographic prior. Russian, Chinese, and Eastern-European clinical practice prior toward "Cerebrolysin works" is established before any given RCT begins; the trial designs and outcome interpretations show this.
- Bryan Johnson asymmetry. His positive endorsements get more US-clinic marketing traction than his null Cerebrolysin result. The asymmetry is informative.
- Pediatric placebo refusal. Parents refused enrollment in placebo arms; citation flag. The resulting "RCTs" are not blinded.
Manipulation Flags (Mode 2: Manipulation Shield)
- Industry marketing: EVER Pharma copy ("brain self-repair," "neuroregeneration," "CNS regeneration") propagates verbatim through US IV-clinic marketing (NexGen, Unchained, Wellness Century City, Axon, InfuzeMD, RWA). Marketing-as-content laundering is well-developed.
- Influencer economics: Jonathan Roseland (Limitless Mindset) is a disproportionate share of English-language enthusiast content and runs an affiliate program with CosmicNootropic and RuPharma. The "BDNF +600%" stat is laundered repeatedly across his pages and sister sites. Bryan Johnson's name is leveraged by clinics without disclosing his null result.
- Counter-narrative manipulation: Pharma fearmongering does NOT appear to be a major Cerebrolysin issue (no major US competitor stands to lose meaningful share; citicoline and piracetam are also mostly off-label or unapproved). The Cochrane null finding cuts against the manufacturer; the manufacturer-affiliated EAN/EFNR 2021 guideline cuts the other way. Both sides are visible.
- Cui bono summary:
- Wins if you take it: EVER Neuro Pharma; US IV clinics ($200-500/session, $2,000-5,000/course); Russian/Eastern-European pharmacy distributors; English-language vendor-affiliate sites.
- Wins if you don't: Established US neurology guidelines (lower complexity); patients who avoid the non-fatal SAE signal at the 30-mL × 10-d stroke dose.
- Neutral: Compounding-pharmacy ecosystem (Cerebrolysin is not a 503A bulk substance, so the compounding industry has no stake either way).
- Red team highlight: The Sharma/Masliah research-integrity scandal is the single most concerning angle. A meaningful portion of the Western preclinical literature supporting Cerebrolysin is currently under PubPeer scrutiny, with multiple retractions and a sacked NIH author. Anyone citing pre-2024 Cerebrolysin Western preclinical literature without checking PubPeer is exposed.
Decision Support (Mode 3: Clarity Compass)
- Health utility score: 5/10. Compound-intrinsic. Driven by: (a) 3/5 stroke-aphasia + 3/5 TBI + 3/5 AD signals across multiple indications; (b) modest effect sizes; (c) one negative Cochrane on the largest indication; (d) research-integrity concerns about a chunk of the supportive literature; (e) NULL evidence in healthy adults; (f) cross-domain breadth tempered by repeated null/weak findings.
- Opportunity cost: High. IV/IM administration, course-based ($60-150 retail import per 10-day course; $2,000-5,000 at US IV clinic), painful IM, anaphylaxis risk, no FDA approval (no insurance coverage), porcine origin (religious-dietary considerations), import friction.
- Verdict: CONDITIONAL.
- Conditions (when warranted):
- TBI within 48-72h of injury; CAPTAIN-protocol use is the most defensible indication.
- Post-stroke motor recovery in active rehabilitation; CARS-protocol use; the rehab is the active comparator base.
- Post-stroke aphasia + speech-language therapy; ESCAS-protocol use (one pilot RCT; awaiting replication).
- Mild-moderate Alzheimer's with patient/family seeking adjunct; modest symptomatic benefit; cycle-based.
- CADASIL; only inside the active Phase 2 NCT05755997 enrollment.
- Conditions when NOT warranted:
- Healthy-adult cognitive enhancement (Bryan Johnson null; Longecity self-survey biased)
- Acute stroke in a patient already receiving full standard-of-care thrombolysis/thrombectomy without informed-consent acknowledgment of the Cochrane non-fatal SAE signal
- Pediatric off-label without specialist supervision
- Pregnancy/lactation
- Active malignancy or recent cancer history
- Religious-dietary porcine restriction
- Anyone unable to access authentic EVER-Pharma product (counterfeit risk via "cerebroprotein hydrolysate" generics)
Bottom Line
Cerebrolysin is one of the rare cases where regulatory approval (50+ countries), guideline-level endorsement (EAN/EFNR 2021, Russian MoH, Mexican COFEPRIS), and a strong Cochrane null on the primary indication coexist. The honest read: there is a real, modest, multivariate-detectable benefit in subacute stroke motor recovery, post-stroke aphasia, and TBI when used as part of structured rehabilitation; there is a Cochrane null and non-fatal SAE harm signal in acute-stroke neuroprotection at the 30-mL × 10-d dose; there is no disease-modifying effect in Alzheimer's; there is no documented effect in healthy adults; there is a meaningful research-integrity scandal compromising a chunk of the supportive literature; and there is a real composition-equivalence problem at the consumer-product layer. CONDITIONAL; narrow, specific use cases under specialist supervision, with informed consent acknowledging the bifurcated evidence base.
Practical Notes
Brands & Product Selection
- Authentic: EVER Neuro Pharma GmbH (Unterach am Attersee, Austria) is the original and only validated manufacturer. Confirm batch number, ampoule labeling, and pharmacy chain of custody. EVER product is licensed under the trade name "Cerebrolysin" in approved countries.
- Trade names in approved markets: Cerebrolysin (Austria, Germany, Russia, EU Eastern Europe), Cerebrolysin (Mexico, COFEPRIS), Cerebroprotein hydrolysate (China; but generic substitution risk; insist on EVER-imported ampoules).
- Avoid: "Cerebroprotein hydrolysate" generics from Indian and Chinese manufacturers; Seidl & Aigner 2024 documented bioactivity loss. US research-chemical vendors (Pure Lab Peptides, Nu Science Peptides, Peptide.shop, Nationwide Peptides) sell powder-format products of unverifiable composition.
- Vendor channels (rank-ordered by quality): Russian pharmacies (RuPharma, CosmicNootropic, Apteka.ru) shipping authentic EVER ampoules > Mexican border pharmacies (anecdotal authentic product) > EU pharmacy direct-import (RxEli, MedixLife, Tdawi, Bloom Pharmacy) > US research-chemical vendors (avoid).
- Quality markers: glass ampoule (not vial); EVER Neuro Pharma label; batch number; expiration date 24-36 months from manufacture; clear amber-yellow solution (no precipitate, no cloudiness).
Storage & Handling
- Ampoules: store 15-25°C protected from light before opening. Do not refrigerate intact ampoules; protein precipitation can occur.
- After opening: use immediately. Discard any unused portion of an opened ampoule.
- Diluted IV admixtures: stable in 100-250 mL 0.9% saline or 5% dextrose for up to 24h refrigerated; manufacturer recommends use within 4h of dilution at room temperature.
- Shelf life: 4 years from manufacture date when stored properly.
- Light-sensitive: keep in original carton until use.
- Travel: room temperature for up to 30 days is acceptable; protect from direct sunlight and >40°C.
Palatability & Compliance
Not applicable for IV. For self-administered IM:
- Cerebrolysin IM is famously painful; community reports describe "burning" lasting 2-5 minutes after injection.
- Mitigation strategies: warm ampoule to body temperature in the hand for 10 minutes before drawing; inject slowly (>30 seconds for 5 mL); deep-IM (gluteal or vastus lateralis, not deltoid for >2 mL); rotate injection sites across courses.
- Compliance challenge: the 10-20 day daily-injection course is the friction point. Pain dropout is real; ~10-20% of community self-administrators discontinue mid-course.
Exercise & Circadian Timing
- Morning dosing strongly preferred. Cerebrolysin has cholinergic-like activation effects; evening dosing causes insomnia and agitation in a meaningful subset of users (community-frequent complaint; aligned with manufacturer label).
- No specific exercise interaction documented. Russian post-stroke rehab protocols pair Cerebrolysin IV in the morning with afternoon PT/OT; this pattern likely reflects the circadian preference and the practical structure of inpatient rehab, not a specific exercise-Cerebrolysin synergy.
- Caffeine: no documented interaction; community reports common co-use without issue.
Reference Ranges (Expected Biomarker Changes)
| Biomarker | Baseline Range | Expected Change | Timeline |
|---|---|---|---|
| ARAT day-90 (stroke motor recovery) | 0-57 | Effect size MW 0.62-0.71 vs placebo + rehab | Day 90 (CARS protocol) |
| NIHSS (acute stroke) | 0-42 | +1.39 points improvement vs placebo (Patel 2025 MA) | Day 14-30 |
| Western Aphasia Battery | 0-100 | +14.8 points vs placebo (ESCAS pilot) | Day 90 |
| 13-scale TBI multidimensional ensemble (CAPTAIN) | composite | MW 0.59-0.60 vs placebo | Day 90 |
| ADAS-cog (AD) | 0-70 (higher = worse) | SMD -0.40 at 4 weeks (Gauthier MA); attenuates by 6mo | 4-26 weeks |
| Plasma EV Aβ / tau (AD biomarker) | Variable | Modulated; Alvarez 2022 PMID 36155516 | 4-12 weeks |
| BDNF (in donepezil-cotreatment AD) | Variable | Reported +600% in one trial; context-dependent, NOT generalizable | Variable |
| Bryan Johnson healthy-adult biomarker panel | Healthy ranges | NULL; no measurable change after 3 months | 3 months |
Cost
| Channel | Per 10-day course (5 mL/d × 10 IM) | Per 21-day stroke course (30 mL/d × 21 IV) | Notes |
|---|---|---|---|
| Russian pharmacy direct-import (RuPharma, CosmicNootropic) | $60-100 | $200-400 | Authentic EVER product, ships to US |
| EU pharmacy direct-import (RxEli, MedixLife) | $80-150 | $300-500 | Authentic EVER product |
| Mexican border pharmacy | $100-200 | $400-700 | Anecdotal authentic |
| US IV clinic (NexGen, Unchained, Wellness Century City, Axon) | N/A (clinics use IV not IM) | $2,000-5,000 | Pricing poorly disclosed; clinic markup substantial |
| US research-chemical vendor (avoid; composition unverified) | $50-150 | $200-500 | Counterfeit / generic substitution risk |
Cost-effectiveness: in approved-country healthcare systems, Cerebrolysin is reimbursed for inpatient stroke/TBI care. For US out-of-pocket users, the IV-clinic markup makes per-course cost roughly 10-20× the EU/Russian pharmacy retail import.
What We Don't Know
- Whether Cerebrolysin closes the sex gap in stroke outcomes (no primary sex-stratified outcome reported)
- Whether the CARS motor-recovery effect replicates in a fully independent (non-EVER-affiliated) multicenter RCT
- Whether the ESCAS aphasia pilot replicates in larger trials
- Whether Cerebrolysin has any measurable effect in healthy adults beyond Bryan Johnson's null self-trial
- The PubPeer-status-cleared subset of the Sharma/Masliah literature (re-verification needed paper-by-paper)
- Long-term (>5 year) safety in any indication
- Whether the Cochrane non-fatal SAE signal at 30-mL × 10-d is dose-dependent (would lower doses preserve any benefit while reducing harm?)
- Composition equivalence; is any generic "cerebroprotein hydrolysate" bioactivity-validated?
- WADA classification; does the S2 peptide-mimetic catch-all apply to Cerebrolysin?
- Pediatric Western multicenter safety and efficacy data
- Whether the post-COVID anosmia signal (NCT04830943, PMID 37950370) replicates
- The CADASIL Phase 2 result (NCT05755997 active not recruiting)
References
Cochrane reviews (independent)
- Ziganshina LE et al. (2023); Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. PMID 37818733. 7 RCTs n=1773; RR death 0.96 (NS); non-fatal SAE RR 2.39 (1.10-5.23); moderate certainty. Conclusion: probably no benefit on death; signal of harm.
- Ziganshina LE et al. (2020); Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. PMID 32662068. Predecessor; same conclusion.
- Cui S et al. (2019); Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. PMID 31710397. 6 RCTs n=597; cognition SMD 0.36 (very low quality); "may be too small to be clinically meaningful."
- Chen N et al. (2013); Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. PMID 23440834. Original; insufficient evidence.
Landmark RCTs
- Heiss WD et al. (2012); CASTA Asian acute stroke. Stroke 43:630-6. PMID 22282884. n=1070; primary endpoint NEUTRAL; post-hoc severe-stroke subgroup favorable trend.
- Muresanu DF et al. (2016); CARS-1 Cerebrolysin and Recovery After Stroke. Stroke 47:151-9. PMID 26564102. n=208; ARAT day-90 MW 0.71 (CI 0.63-0.79), p<0.0001.
- Guekht A et al. (2017); CARS pooled MA. Neurol Sci. PMID 28707130. n=442; MW 0.62 ARAT day-90; NNT 7.1 NIHSS day-14.
- ESCAS investigators (2025); Speech therapy + Cerebrolysin in non-fluent aphasia. Stroke 56:937-47. PMID 39957612. n=132; +14.8 WAB points vs placebo.
- Staszewski J et al. (2025); Cerebrolysin + thrombectomy. Transl Stroke Res. PMID 40325343. mRS 0-2 OR 2.7 at 90d.
- Staszewski J et al. (2026); Cerebrolysin post-thrombectomy 12-mo. Transl Stroke Res. PMID 41739286. aOR 6.10 (1.64-22.66).
- Poon W et al. (2020); CAPTAIN-I TBI. Neurol Sci. PMID 31494820. n=46; underpowered, terminated.
- Muresanu DF et al. (2020); CAPTAIN-II TBI. Neurol Sci. PMID 31897941. n=139; MW 0.59, p=0.0119.
- Vester JC et al. (2021); CAPTAIN pooled MA. Neurol Sci. PMID 33620612. n=185; SMD 0.34.
- Alvarez XA et al. (2011); Cerebrolysin AD dose-finding. Eur J Neurol. PMID 20500802. n=251; positive on global function.
- Alvarez XA et al. (2011); Cerebrolysin + donepezil AD combo. Curr Alzheimer Res. PMID 21679156. n=197; equivalence + combo trends best on global.
Meta-analyses (manufacturer-aligned)
- Gauthier S et al. (2015); Cerebrolysin in mild-moderate AD MA. Curr Med Res Opin. PMID 25832905. 6 RCTs; cognition SMD -0.40 at 4 wk; global change OR 4.98 at 6 mo.
- Bornstein NM et al. (2018); Early post-stroke recovery MA. PMID 29248999. 9 RCTs n=1879; MW 0.60 NIHSS day-30.
- Strilciuc S et al. (2021); Stroke safety MA. PMID 34959697.
Mechanism
- Seidl R, Aigner R (2024); Comparing biological activity and composition of Cerebrolysin with other peptide preparations. PMID 38737662. Generic bio-similars LACK Cerebrolysin's neurotrophic activity.
- Seidl R (2024); NF-L reporter cell-line bioassay. PMID 38304771.
- Cárdenas-Bedoya J et al. (2025); BDNF + dendritic plasticity in amygdala. PMID 40123021.
- Martínez-Torres C et al. (2024); GAP-43 + motor recovery post-kainic-acid. PMID 39580783.
- Hosseini M et al. (2025); CREB/PGC-1α + mitochondrial. PMID 41204270.
- Chan A et al. (2025); Microglial polarization SR. PMID 40971139.
- Akbari-Gharalari N et al. (2026); Cerebrolysin-loaded PRP exosomes in SCI. PMID 40470992.
Pediatric
- Onose G et al. (2018); Communication defects after perinatal brain insult. PMID 26365023. n=158; social +65%, speech +46%, symbolic +358%.
- El-Banna F et al. (2021); Preterm <32 wk neurodevelopment RCT. PMID 33935111. n=60; failed gross-motor 33% vs 70%.
- Onose G et al. (2017); Cerebral palsy gross motor RCT. PMID 28074392. n=50; GMFCS 2.1 vs 3.16.
- Chutko LS et al. (2017), Autism spectrum disorder. PMID 29053124. Russian RCT, placebo refused by parents; integrity flag.
Off-label
- Aboul-Enein FH et al. (2023); Cerebrolysin for post-COVID olfactory dysfunction. PMID 37950370. RCT, signal favorable.
Regulatory / Guideline / Safety
- Beghi E et al. (2021); EAN/EFNR guideline on pharmacological support in early motor rehabilitation after AIS. PMID 34152062. Recommends Cerebrolysin 30 mL/day IV ≥10 d. Manufacturer-affiliated panel COI.
- Trimmel H et al. (2024); Life-threatening anaphylaxis to Cerebrolysin. PMID 39055722. 85-yo subacute stroke patient; well-documented case report.
- Doppler/Rockenstein retraction (2026), Neurotrophic effects of Cerebrolysin in Mecp2(308/Y) Rett syndrome model, RETRACTED. PMID 41874695. Integrity flag.
Investigation / Critical commentary
- For Better Science (2024); "Cerebrolysin: Sharmas, Masliah, and EVER Pharma." Investigation flagging 25/39 Sharma + 8/21 Masliah cerebrolysin papers. https://forbetterscience.com/2024/10/08/cerebrolysin-sharmas-masliah-and-ever-pharma/